A small device implanted just beneath the skin, roughly the size of a large postage stamp and weighing about two grams, kept ...

The FDA has approved Awiqli, the first once‑weekly long‑acting basal insulin, for adults with type 2 diabetes, which offers ...

CNW/ -- (SSE: 603087) today announced that two pivotal phase 3 clinical trials, SUPER-1 and SUPER-2, evaluating ...

Some patients with type 2 diabetes will be able to switch from daily insulin injections to this first-of-its-kind once-weekly ...

For over a century, scientists have chased the dream of insulin pills, but the digestive system kept destroying the drug ...

People with diabetes have more than a few hassles, particularly at meals. They not only have to measure their blood glucose levels and inject the right amount of insulin, but carry all the relevant ...

“Insulin injections remain a daily burden for many patients,” said Shingo Ito, an associate professor at Kumamoto University ...

Most diabetes patients must carefully monitor their blood sugar levels and inject insulin multiple times per day, to help ...

(1,2) "Awiqli (R) is an important new option that meets a real need as the first FDA-approved, once-weekly basal insulin for adult patients with type 2 diabetes. It's helping to reframe what basal ...

Add Yahoo as a preferred source to see more of our stories on Google. Weekly insulin shots can help control both Type 1 and Type 2 diabetes as well as daily injections do, a pair of clinical trials ...

Researchers in Japan have reported a significant step in the long‑standing scientific effort to develop an insulin medication ...

“Insulin injections remain a daily burden for many patients,” said Associate Professor Shingo Ito. “Our peptide-based ...